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Research Report
Background
In recent decades, several reports have highlighted the 
importance of potential drug-drug interactions (pDDIs) as a 
risk factor for adverse drug events.1,2 Nevertheless, the 
impact of DDIs on a public health level remains controver-
sial: rates for hospitalizations attributable to DDIs vary 
between 0.1% and 6.2%, depending on study size and 
patient population.3,4 Additionally, DDIs have been associated 
with increased length of stay and cost of hospitalization.5 
However, not all pDDIs are clinically relevant, and many 
can be managed safely.6,7
Although precautionary measures, such as DDI alert sys-
tems, are well established, coprescribing of drug combina-
tions that potentially cause severe DDIs,6-11 such as tizanidine 
and ciprofloxacin,12 persists. Tizanidine is a central 
α
2
-adrenoceptor agonist with a narrow therapeutic range, 
which is approved in Switzerland for the treatment of spas-
ticity.13,14 Its metabolism is mainly mediated by cytochrome 
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Abstract
Background: Potential drug-drug interactions (pDDIs) are described in various case reports, but few studies have evaluated 
the impact of specific combinations on a population level. Objective: To analyze the type and frequency of multiple 
contraindicated (X-pDDIs) and major interactions (D-pDDIs) and to subsequently assess the impact of the particular 
combination of tizanidine and ciprofloxacin on outpatient physician visits and hospitalizations. Methods: Anonymized 
Swiss claims data from 524 797 patients in 2014-2015 were analyzed. First, frequencies of X- and D-pDDIs were calculated. 
Next, a retrospective cohort study was conducted among patients prescribed tizanidine and ciprofloxacin (exposed, n = 
199) or tizanidine and other antibiotics (unexposed, n = 960). Hospitalizations and outpatient physician visits within 7, 14, 
and 30 days after initiation of antibiotic therapy were evaluated using multiple binary logistic regression and multiple linear 
regression. Results: The relative frequencies of X- and D-pDDIs were 0.4% and 6.65%, respectively. In the cohort study, 
significant associations between exposure to tizanidine and ciprofloxacin and outpatient physician visits were identified for 
14 and 30 days (odds ratio [OR] = 1.61 [95% CI = 1.17-2.24], P = 0.004, and OR = 1.59 [95% CI = 1.1-2.34], P = 0.016). 
A trend for increased risk of hospitalization was found for all evaluated time periods (OR = 1.68 [95% CI = 0.84-3.17], 
OR = 1.52 [95% CI = 0.63-3.33], and OR = 2.19 [95% CI = 0.88-5.02]). Conclusion and Relevance: The interaction 
between tizanidine and ciprofloxacin is not only relevant for individual patients, but also at the population level. Further 
investigation of the impact of other clinically relevant DDIs is necessary to improve patient safety and reduce avoidable 
health care utilization.
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P450 1A2-isoenzyme. Ciprofloxacin, a quinolone antibiotic, 
has been shown to be a clinically relevant inhibitor of 
CYP1A2.15 In a pharmacokinetic study, ciprofloxacin 
increased the area under the plasma-concentration curve of 
tizanidine by an average of 10-fold (range 6-fold to 
24-fold).15 Case reports highlight the potential threat to 
affected patients, with adverse reactions such as cardiovas-
cular (eg, severe hypotension) and central nervous system 
(CNS)-depressive effects (eg, drowsiness) reported.12,14-16 
A recent analysis of the World Health Organization’s data-
base on adverse drug reactions (VigiBaseTM) identified 64 
individual tizanidine-related cases involving ciprofloxacin, 
4 of which had a fatal outcome.17
Objectives
This study comprised 2 parts. In the first explorative analy-
sis, the frequency and type of different pDDIs occurring in 
Switzerland were established. Multiple interactions rated as 
contraindicated (X) or major (D) were investigated using a 
large claims database.
From this overview, we evaluated the risk of hospitaliza-
tion and outpatient physician visits (“visits”) associated 
with 1 contraindicated pDDI in the second part of the study. 
With respect to its contraindication, a relatively large num-
ber of patients were prescribed the combination of tizani-
dine and ciprofloxacin. Whereas the severity of the 
interaction has been well described in individual patients, 
its impact on the risk of hospitalization or visits has not yet 
been examined on a larger scale. Therefore, we selected this 
particular interaction for further evaluation.
Methods
Characteristics of the Study Population
Anonymized claims data was provided by a large health 
insurance company in Switzerland (Helsana Group). The 
data set encompassed 524 797 insured Swiss patients (age 
≥ 18 years), accounting for 22 768 948 drug-prescriptions 
in 2014 and 2015. All participants were insured at the 
health insurance company for the entire course of the study, 
and no additional private insurance was allowed. All 
patients had at least 5 drug prescriptions within 1 calendar 
year. Participants who died within that period were 
excluded because legal requirements meant that the date of 
death was unavailable. The data set contained records of all 
health care invoices, information on prescribed drugs, 
health care utilization (eg, hospitalization, physician vis-
its), demographic parameters, health insurance status, and 
costs for each patient.18 The representativeness of the study 
population was also examined (Supplement 1; supplemen-
tary material available at http://journals.sagepub.com/
home/aop/supplemental-data).
Ethical Approval
The harmlessness of the study was attested by the Cantonal 
Ethics Committee of Zurich, although no formal ethical 
approval was required under Swiss law. The concept of ano-
nymization was approved by the Cantonal Data Security 
Officer.
Frequency and Type of Interactions
Potential DDIs were defined as the prescription of 2 drugs 
within a 7-day period. All combinations labeled “contrain-
dicated” (X, n = 663) and “to be avoided” (D, n = 1785) in 
the Matrix database were evaluated (Supplement 2). Matrix 
is a DDI database from the Department of Clinical 
Pharmacology and Toxicology, University Hospital Zurich, 
Switzerland. Interactions are ranked by severity using a 
validated decision model, which has been described in 
detail elsewhere.19 Frequency analyses were carried out for 
2014 data, and stratification for age, sex, and number of dif-
ferent drugs was performed. Similar results were expected 
for 2015 data. Frequently implicated drug classes were 
described, and interactions were grouped with respect to the 
main potential (adverse) effect.
Interaction Between Tizanidine and 
Ciprofloxacin
Cohort Study Design. A cohort study was conducted with 
respect to hospitalizations and visits within 7, 14, and 30 
days after starting antibiotic therapy in patients prescribed 
tizanidine between February 2014 and November 2015. 
The study design is illustrated in Figure 1. Exposed patients 
(ciprofloxacin and tizanidine, n = 199) were compared with 
a group of patients who were unexposed to ciprofloxacin 
(and, thus, to the ciprofloxacin-tizanidine interaction), but 
who were also prescribed tizanidine and a concomitant anti-
biotic with an antibiotic spectrum and indication compara-
ble to those of ciprofloxacin (n = 960).
Definition of Exposed and Unexposed Patients. Exposure was 
predefined as the prescription of tizanidine and ciprofloxa-
cin within the same 7-day period (n = 321). Among exposed 
patients, only those prescribed tizanidine before or on the 
same day as ciprofloxacin as the first occurrence were 
included. This definition was selected to increase the prob-
ability of concurrent exposure because the treatment dura-
tion of ciprofloxacin may vary with respect to the indication. 
Thus, potential cases may have been missed under this defi-
nition. If the drug combination was coprescribed within 7 
days on multiple occasions for a patient during the study 
period, only the first occurrence of tizanidine-ciprofloxacin 
was evaluated (n = 231). The start date of ciprofloxacin was 
defined as the index date. To ensure comparability with the 
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unexposed group, patients prescribed ciprofloxacin in the 
30 days prior to the index date were excluded, as were those 
prescribed any other antibiotic either at the index date or in 
the 7 days prior to the prescription of tizanidine. In total, 
data from 199 exposed patients were analyzed.
Unexposed patients were those prescribed tizanidine 
together with an antibiotic other than ciprofloxacin within 
the same 7-day period (n = 1422). Patients were included 
only if tizanidine was prescribed before or on the same day 
as the other antibiotic. If the drug combination was pre-
scribed multiple times within separate 7-day periods for a 
patient during the study period, only the first occurrence of 
tizanidine-antibiotic (index date) was evaluated. Patients 
for whom a coprescription of antibiotic-tizanidine occurred 
in the 3 months prior to the index date were excluded. 
Patients prescribed more than 1 antibiotic at the index date 
or prescribed an antibiotic in the 7 days prior to the pre-
scription of tizanidine were excluded, as were patients pre-
scribed ciprofloxacin 30 days before or after the index date, 
to eliminate ciprofloxacin from the unexposed group. The 
final number of patients in the unexposed group was 960.
No additional restrictions regarding the prescription of 
either tizanidine or antibiotics before or after the index date 
were made in either group. No patients were prescribed either 
enoxacin or fluvoxamine, potent CYP1A2 inhibitors, in the 
90 days before and 30 days after the index date. The patient 
inclusion process is displayed in a flowchart (Figure 2).
Investigated Outcomes. Both hospitalizations (“Hospitaliza-
tion”, binary) and visits (“Visits”, binary and log[count]) 
were evaluated as adverse outcomes. Information on diag-
noses for hospital admissions or reasons for visits were 
unavailable. Hospitalizations were identified using Swiss 
Diagnosis Related Group Codes, which are case-based 
lump sums used for the invoicing of inpatient hospitaliza-
tion services.20 Visits were identified using invoice codes 
for outpatient medical treatments,21 and both visits at the 
physician’s office and home visits by the physician were 
considered.
Statistical Methods. Data were analyzed using R (version 
3.3.1). For dichotomous variables, absolute and relative 
frequencies were calculated. For continuous variables, 
medians and interquartile ranges (IQRs) were provided. To 
identify associations between 2 discrete variables, the 
Fisher exact test was used. Associations between continu-
ous and discrete variables with 2 levels were assessed using 
the Mann-Whitney test. Because the exposed patient group 
contained only 199 patients, age categories were trans-
formed to a continuous variable by applying a stratified 
imputation. Multiple regression models adjusting for con-
founders were used to verify whether there was an associa-
tion between the concurrent use of ciprofloxacin and 
tizanidine (exposed) and the baseline unexposed group with 
respect to the evaluated outcomes. Multiple logistic regres-
sion, adjusting for demographical variables, was applied for 
the binary outcomes of hospitalization or visit. Odds ratios 
were computed, and the number of visits was transformed 
logarithmically, with multiple linear regression adjusting 
for age, sex, and number of different drugs prescribed. 
Model selection was assisted by the Akaike information cri-
terion. Power analysis was conducted using STATA (ver-
sion 13.1, StataCorp LP). Values of P <0.05 were considered 
statistically significant.
Results
Frequency and Type of Interactions
X-pDDIs were identified in 0.4% (n = 2119) of patients, 
and D-pDDIs were found in 6.65% (n = 34 885) of the 
study population (n = 524 797). Women were affected 
more frequently than men (X-pDDI: 0.34% for men, 0.45% 
for women; D-pDDI: 5.8% and 7.3%, respectively). The 
frequency of patients affected by interactions increased 
both with age (X-pDDI: 0.24% for age 25-34 years, 0.61% 
for age 75-84 years; D-pDDI 3.6% and 9.9%, respectively) 
and the number of different drugs prescribed per year 
(X-pDDI: 0.16% for 6-10 drugs, 1.67% for ≥16 drugs; 
D-pDDI 4.29% and 21.5%, respectively). Drug classes 
most frequently involved were propulsives (A03F, 16.5%), 
macrolides, lincosamides, and streptogramins (J01F, 13.9%) 
as well as antimycotics for systemic use (J02A, 8.3%) for 
X-interactions and NSAIDs (M01A, 17.4%), antithrombotic 
Figure 1. Cohort study design: Tizanidine patients were prescribed antibiotic therapy at the index date, with an exposed group 
prescribed ciprofloxacin and an unexposed group prescribed an antibiotic other than ciprofloxacin. Outcomes (outpatient physician 
visits, hospitalizations) were evaluated 7, 14, and 30 days after the index day.
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agents (B01A, 16.9%), and hypnotics/sedatives (N05C, 
13.1%) for D-labeled interactions. The 5 most frequently 
contraindicated pDDIs in patients were domperidone/clar-
ithromycin (n = 326), methotrexate/metamizole (n = 254), 
domperidone/fluconazole (n = 237), ciprofloxacin/tizani-
dine (n = 169), and clarithromycin/atorvastatin (n = 164). 
When evaluated with respect to potential (adverse) effects 
of both X- and D-DDIs, highest frequencies among affected 
patients were found for interactions that increased risk of 
bleeding (n = 15 077, 32.7%), caused CNS-depressing 
effects (n = 11 847, 25.7%), and augmented the risk of car-
diac toxicity (n = 9 798, 21.3%).
Figure 2. Inclusion of patients into the exposed and unexposed groups. Other antibiotics included penicillins with/without clavulanic 
acid, macrolides, fosfomycin, other fluoroquinolones, oral cephalosporins, sulfamethoxazole/trimethoprim, nitrofurantoin, and 
tetracyclines.
*Where an unexposed patient received the combination of an antibiotic prescribed within the 7-day period prior to tizanidine treatment, the 
combination must have been prescribed at least 3 months prior to the index date.
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Interaction Between Tizanidine and 
Ciprofloxacin
Descriptive statistics are summarized in Table 1. A note-
worthy discrepancy between the groups was found for the 
age variable. The composition of antibiotic prescriptions 
received by unexposed patients at the index date involved 
multiple groups of antibacterials: penicillins with/without 
clavulanic acid (n = 354, 36.9%), macrolides (n = 154, 
16%), fosfomycin (n = 145, 15.1%), other fluoroquinolones 
(n = 101, 10.5%), oral cephalosporins (n = 79, 8.2%), sulfa-
methoxazole/trimethoprim (n = 61, 6.4%), nitrofurantoin 
(n = 36, 3.8%), and tetracyclines (n = 30, 3.1%).
The risk of at least 1 visit after starting ciprofloxacin sig-
nificantly increased at 30 and 14 days by as much as 1.6-
fold. No significant association was found at 7 days. No 
relevant increase in the number of visits was identified for 
any of the 3 observation periods (Table 2).
Exposure to concomitant tizanidine and ciprofloxacin 
was associated with an increased risk of hospitalization 
within 7, 14, and 30 days after prescription of the antibiotic 
by 1.52- to 2.19-fold, respectively (statistically nonsignifi-
cant). A power analysis for the 30-day time frame (2-sample 
proportion tests corrected for allocation ratio [0.2070, n = 
1159], significance level = 0.05) revealed a power of 0.44. 
This indicates that the study did not have sufficient power 
to detect a difference between the 2 groups with respect to 
hospitalization. No significant differences in the frequency 
of hospitalizations and visits at 7, 14, and 30 days before 
and after the index date were observed (data not shown).
Discussion
Our results illustrate the relevance of the interaction 
between tizanidine and ciprofloxacin on a public health 
level: this interaction was among the most frequent contra-
indicated interactions, and the probability of a visit increased 
significantly by 1.6-fold when tizanidine and ciprofloxacin 
were prescribed concomitantly at 30 and 14 days.
Interaction Between Tizanidine and 
Ciprofloxacin
Outpatient Physician Visits. Switzerland has approximately 
6.7 million inhabitants older than 18 years, and approxi-
mately 239 000 of these have received tizanidine. Given the 
frequency of 0.58% for the ciprofloxacin-tizanidine interac-
tion in tizanidine patients from our study population, we 
extrapolate that 1386 patients in Switzerland may be 
affected by this interaction annually. According to our find-
ings, 64.8% of these patients would attend at least 1 visit 
within 14 days of treatment (n = 898). If this interaction 
could be avoided (unexposed patients: 52.9% visits), 
approximately 165 patients forgo the need for a visit.
Additional visits do not only have economic conse-
quences: they ultimately indicate a medical condition. In 
contrast to hospitalizations, visits have rarely been studied 
as adverse outcomes in the literature. It can be assumed 
that, in many cases, patients may first contact their attend-
ing physician when they experience DDI-related adverse 
reactions or feel unwell during treatment rather 
Table 1. Descriptive Statistics for Exposed (Ciprofloxacin and Tizanidine) and Unexposed (Other Antibiotic and Tizanidine) Groups.
Exposed Group (n = 199) Unexposed Group (n = 960)
P Value Absolute Frequency Relative Frequency Absolute Frequency Relative Frequency
Sex
 Male 66 33.2% 277 28.9% 0.23
 Female 133 66.8% 683 71.1%  
Age
 Median 58.3 54.4 0.06
 IQR (46.5-69.4) (41.8-68.2)  
Number of different drugsa
 Median 20 18 0.44
 IQR (13-26) (12-27)  
Package strength tizanidineb
 2-mg Tablet 61 30.7% 296 30.8% 0.59
 4-mg Tablet 114 57.3% 572 59.7%  
 6-mg MR Capsule 23 11.6% 75 7.8%  
 12-mg MR Capsule — 7 0.7%  
 Combination 
multiple strengths
1 0.5% 10 1.0%  
aNumber of different drugs prescribed in the year of index date.
bPackage(s) last prescribed before the index date.
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Table 2. Results of Multiple Logistic and Linear Regression Analysis for Hospitalizations and Outpatient Physician Visits.a
Outcome (Y)
Y = 1/n (Exposed; 
Unexposed) Age Sex, M
Number 
of Drugs Exposure
Hospitalization (0/1)
30 Days
 β 13/199; 36/960 0.021 0.47 0.034 0.517
 OR 1.02 1.6 1.03 1.68
 95% CI (OR) 1.00-1.04 0.86-2.87 1.01-1.06 0.84-3.17
 P Value 0.02 0.12 0.005 0.13
Hospitalization (0/1)
14 Days
 β 8/199; 24/960 0.017 0.543 0.037 0.422
 OR 1.02 1.72 1.04 1.52
 95% CI (OR) 0.995-1.04 0.81-3.52 1.01-1.07 0.63-3.33
 P Value 0.13 0.14 0.01 0.32
Hospitalization (0/1)
7 Days
 β 8/199; 17/960 0.014 0.489 0.026 0.785
 OR 1.01 1.63 1.03 2.19
 95% CI (OR) 0.99-1.04 0.7-3.64 0.99-1.06 0.88-5.02
 P Value 0.27 0.24 0.12 0.07
Visit (0/1)
30 Days
 β 155/199; 658/960 0.006 0.172 0.067 0.463
 OR 1.01 1.19 1.07 1.59
 95% CI (OR) 0.998-1.01 0.89-1.6 1.05-1.09 1.1-2.34
 P Value 0.15 0.25 <0.001 0.016*
Visit (0/1)
14 Days
 β 129/199; 508/960 0.002 0.214 0.044 0.478
 OR 1.00 1.24 1.05 1.61
 95% CI (OR) 0.99-1.01 0.95-1.61 1.03-1.06 1.17-2.24
 P Value 0.64 0.11 <0.001 0.004**
Visit (0/1)
7 Days
 β 80/199; 353/960 0.005 0.2 0.031 0.109
 OR 1.00 1.22 1.03 1.12
 95% CI (OR) 0.998-1.01 0.94-1.59 1.02-1.04 0.81-1.53
 P Value 0.19 0.14 <0.001 0.50
Visit [log(count)]
30 days
 β 0.001 0.122 0.021 0.07
 exp(β) 1.00 1.13 1.02 1.07
 95%CI [exp(β)] 0.999-1.003 1.05-1.22 1.02-1.025 0.98-1.17
 P Value 0.22 0.001 <0.001 0.13
Visit [log(count)]
14 Days
 β 0.0005 0.088 0.013 0.065
 exp(β) 1.00 1.09 1.01 1.07
 95%CI [exp(β)] 0.999-1.002 1.02-1.16 1.01-1.02 0.99-1.15
 P Value 0.61 0.008 <0.001 0.10
Visit [log(count)]
7 Days
 β 0.0008 0.055 0.007 0.002
 exp(β) 1.00 1.06 1.01 1.00
 95% CI [exp(β)] 0.999-1.002 1.00-1.11 1.00-1.01 0.94-1.07
 P Value 0.29 0.04 <0.001 0.96
Abbreviation: OR, odds ratio; Y = 1/n: Number of patients with hospitalization or visit in the exposed/unexposed group.
a*P < 0.05; **P < 0.01.
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than requiring hospitalization; therefore, visits are of key 
importance when studying the impact of DDIs. Bourgeois 
et al22 reported a significant trend of increased ADE-related 
visits to outpatient clinics in the United States, from 9.1 to 
16.9 visits per 1000 persons between 1995 and 2005.22 
Emergency department visits have not been evaluated, 
because of low incidence. Fortunately, the ciprofloxacin-
tizanidine interaction can be avoided: for several indica-
tions, ciprofloxacin can be replaced by another antibiotic 
that does not carry the same risk of a pharmacokinetic inter-
action. For tizanidine, pausing treatment during antibiotic 
therapy or drug substitution, depending on the patient’s spe-
cific indication, are 2 options. As underlying medical condi-
tions requiring tizanidine and acute antibiotic therapy are 
expected to increase the risk of hospitalizations and visits, 
confounding by indication was addressed by the inclusion 
of a control group (unexposed) who received antibiotics 
with a spectrum and indication comparable to that of cipro-
floxacin. Cohort studies using a negative control precipitant 
are accepted study designs for the investigation of popula-
tion health effects of pDDIs.23
Patients receiving several classes of oral antibiotics were 
combined to form an appropriate control group. Given the 
small number of patients receiving tizanidine and other qui-
nolones, and the broader spectrum of indications for cipro-
floxacin compared with other quinolones, a control group 
comprising only quinolones was not established.
Previous pharmacokinetic studies indicated a rapid 
increase in tizanidine exposure after the initiation of 
concomitant ciprofloxacin therapy, meaning that possi-
ble adverse reactions requiring health care utilization 
were expected to occur within a short time frame. 
Therefore, 7-, 14-, and 30-day periods were chosen, thus 
allowing for evaluation of the development of altered 
risk for adverse outcomes. Interestingly, the weakest 
association between exposure and visits was observed at 
7 days (odds ratio = 1.12; 95% CI = 0.81-1.53), for 
reasons that remain speculative; overlapping effects of 
the underlying disease (antibiotic therapy) may have 
been more common in the initial treatment period. 
Additionally, severe adverse reactions in susceptible 
patients may have appeared rapidly, possibly requiring 
hospitalization rather than a visit.
Hospitalization. The 2.19-fold increased risk of hospitaliza-
tion (95% CI = 0.88-5.02; P = 0.07) shortly after the start of 
ciprofloxacin therapy in patients receiving tizanidine indi-
cates a problematic trend. As expected, the highest risk of 
hospitalization was observed within 7 days of concomitant 
treatment. The clinical relevance of other pDDIs was evalu-
ated for different combinations, including statins/macro-
lides and levothyroxine/warfarin. Whereas some studies 
found an increased risk of hospitalizations,24-27 others could 
not demonstrate an association.28
Frequency and Type of Interactions
We found an overall frequency of contraindicated interac-
tions of 0.4% and a considerably higher rate of 6.65% 
among patients prescribed at least 1 major drug combina-
tion (n = 524 797). Such high rates of severe interactions 
highlight the need for ongoing implementation of DDI-
alerting systems to prevent the prescription of potentially 
harmful combinations.
The frequency of interactions has been analyzed in sev-
eral studies and has depended on the type of interaction 
studied, the definition of interactions, the study setting (eg, 
claims data, clinical study), and the patient population.11 An 
analysis of contraindicated pDDIs in Swiss claims data with 
a focus on the specialization of physicians causing the pDDI 
using the defined daily-dose method revealed rates (0.4% in 
female and 0.5% in male patients)29 similar to that in our 
study. We, therefore, consider our use of a 7-day time frame 
to be a pragmatic and reasonable method to estimate the 
overall frequencies of multiple pDDIs in large data sets.
Time frame methods are commonly used in the literature 
to identify pDDIs.8,9,11,30 We opted for a short time frame of 
7 days to increase the probability of concomitant intake. In 
line with findings from other claims data-based studies,8-11 
we identified higher frequencies of pDDIs associated with 
female gender, increasing age, and number of different 
drugs. Because the study population was older and included 
a higher proportion of female patients compared with the 
general Swiss population (Supplement 1), the frequencies 
of pDDIs may be overestimated when generalized to 
Switzerland. The most frequent possible adverse effects of 
pDDIs in our study were the risk of bleeding, CNS depres-
sion, and cardiac toxicity, which was comparable with pre-
vious findings.8,9
Limitations
This study has several limitations. Calculations were per-
formed under the assumption of immediate intake of the 
prescribed drugs. Because there can be no certainty of 
actual drug intake, all interactions were referred to as 
“potential” DDIs. Formally contraindicated combinations 
may be prescribed intentionally as off-label treatment in 
exceptional cases. Information on over-the-counter medica-
tion and prescriptions during hospitalization was lacking in 
the data set. As interactions involving such medications 
could not be taken into account, the frequency of interac-
tions may be underestimated. As of the conservative 
approach of using a 7-day time frame to define pDDI, the 
frequency of pDDIs may have been underestimated, espe-
cially where pDDIs between continuous therapy and acute 
prescription may have been missed.
Regarding the cohort study, susceptibility to confounding 
by indication was reduced by using a comparable control 
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group, but it might not have been eliminated completely. 
Patterns of antibiotic use for certain indications may vary, 
and the need for physician visits may be associated with the 
severity of infection. No diagnoses describing the indica-
tions for antibiotic therapy were available in the data set. 
Differences between the groups regarding unmeasured 
covariates (eg, comorbidities, prior health care utilization, 
smoking status) cannot be ruled out.
Furthermore, information on the actual admission diag-
noses for hospitalization or reasons for visits was unavail-
able. Finally, the increased risk of hospitalization and visits 
compared with the control group is believed to be largely 
attributable to ciprofloxacin, thus suggesting an impact of 
the interaction. However, no causal relationship can be 
established.
Conclusion and Relevance
The example of concomitant tizanidine and ciprofloxacin 
treatment illustrates that severe DDIs are not only critical 
for individual patients, but may also be relevant on a public 
health level by increasing the risk of health care utilization. 
Because this interaction can be prevented by therapy 
adjustment, adverse outcomes can be avoided. With societ-
ies growing older and rising numbers of patients experi-
encing multimorbidity and polypharmacy, evaluating the 
impact of DDIs from a public health perspective is of 
increasing importance to reduce avoidable health care 
utilization.
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